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To the Editor,
An increasing number of therapies are available to treat asthma, but inhaled corticosteroids (ICS) 
are still the most commonly prescribed and effective controller asthma medication1. Both environmental 
and genetic factors are involved in ICS response. However, few biomarkers have been associated with 
response to asthma treatment with ICS2. Here, we aimed to identify novel markers of ICS response 
combining transcriptomic and genomic data.
A full description of the methods is provided in the Supplementary Methods at the Supporting 
information and it is also summarized in Figure S1. In the discovery stage, RNA sequencing (RNA-seq) 
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available at the Sequence Read Archive (SRA, SRP033351) (https://www.ncbi.nlm.nih.gov/sra) were 
analyzed3. Briefly, this study performed RNA-seq of cell lines from four non-asthmatic lung donors 
treated with control solution or with 1 µM dexamethasone for 18 h3. Raw sequencing data were 
downloaded and processed according to the procedures described in the Supplementary Methods. 
Differential gene expression of cells treated with glucocorticosteroids (GCs) compared to those treated 
with control solution was evaluated using linear models. Differentially dysregulated genes were 
identified after a false discovery rate (FDR) adjustment of 5% (q-value≤0.05).
Differentially expressed genes in the discovery were examined to determine if they also showed 
changes in peripheral blood mononuclear cells (PBMCs) obtained from ICS non-responders (n=3) and 
ICS responders (n=3) from the SLOVENIA study4, defined based on the presence or absence of asthma 
exacerbations despite ICS therapy. RNA libraries were sequenced using the BGISEQ-500 instrument 
(BGI Inc.) and data was analyzed following the same methodology as for the ASM cells. Gene 
expression levels were compared in responders to ICS and ICS non-responder patients, adopting a q-
value≤0.05 to declare significance. Validation of significant differentially expressed genes found in the 
previous datasets was sought using three additional transcriptomic data of ASM cells after GCs 
exposure (GSE13168, GSE34313, and SRP098649), which were combined in a random-effects meta-
analysis. Evidence of replication was considered for genes with consistent effects and q-value≤0.05.
Genetic variants located within 100 kilobases (kb) from the genes with significant changes in 
expression levels across all transcriptomic datasets were examined for association with asthma 
exacerbations despite ICS. For that, ten studies participating in the Pharmacogenomics in Childhood of 
Asthma (PiCA) consortium were analyzed, including 2,681 European and 1,347 Hispanics/Latinos and 
African American children and youth treated with ICS with genome-wide genotyping data available 
(Table S1). Details about each study are described at the Supporting Information and elsewhere4.  
Individuals with asthma exacerbations despite ICS treatment were considered as ICS non-
responders and those without asthma exacerbations as ICS responders. Asthma exacerbations were 
defined by the need for emergency care, hospitalizations, administration of systemic corticosteroids, 
unscheduled doctor visits, and/or school absences because of asthma (Table S1). Association between 
imputed single nucleotide polymorphisms (SNPs) and asthma exacerbations despite ICS treatment was 
tested for each study through logistic regression models including age, sex, and principal components as 
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Bonferroni-like corrected threshold for significance was obtained for each population as α=0.05/total 
number of independent variants.
In the discovery, a total of 14,707 genes were analyzed and 4,718 of them were found to be 
differentially expressed in cells treated with GCs (q-value≤0.05) (Figure 1A). From these genes, 24 
showed significant changes in expression levels depending on ICS response status from asthma patients 
in PBMCs (q-value≤0.05) with consistent alteration across both datasets based on log2 fold change (FC) 
values (Figure 1B, Table S2). Moreover, six out of the 24 genes were replicated with a consistent effect 
of up-regulation in the combined analysis of the three additional transcriptomic datasets of ASM cells 
treated with GCs: LTBP1 (q-value=7.46x10-4), MTURN (q-value=3.92x10-3), NAMPT (q-
value=3.77x10-7), CALD1 (q-value=5.22x10-5), MMD (q-value=5.84x10-4), COL18A1 (q-
value=1.93x10-3) (Table S3). The potential implication of these genes on asthma severity was assessed 
by evaluating their expression in PBMCs according to baseline lung function, showing no significant 
changes (Table S4). Additionally, only LTBP1 remained significantly differentially expressed in 
response to ICS treatment after accounting for baseline lung function (Table S4).
Association of 7,042 SNPs with asthma exacerbations despite ICS use within 100 kilobases from 
the six genes validated was tested in Europeans. After applying a Bonferroni-like correction (p≤4.96x10-
5 for 1,007 independent variants tested), the SNP rs11681246 located within LTBP1 (Figure 1C) was 
significantly associated with asthma exacerbations despite ICS use in Europeans (OR for G allele: 0.72, 
95% CI: 0.63, 0.83, p=3.28x10-6) (Figure 2A-2B). The effect of this association was similar after 
adjusting by treatment step, as a proxy of disease severity, in a subset of 2,282 patients with complete 
information about asthma medication (OR for G allele: 0.74, 95% CI: 0.63, 0.86, p=1.13x10-4).  
However, this SNP was not replicated in non-Europeans. Nonetheless, we assessed the association of 
alternative polymorphisms in non-Europeans, revealing the association of six an intronic LTBP1 variants 
in high linkage disequilibrium (r2>0.95), all dependent from the association of rs76390075 (OR for C 
allele: 0.40, 95% CI: 0.26, 0.63, p=6.76x10-5), after adjustment for 234 independent variants tested 
(p≤2.14x10-4) (Figure 2C-2D). Moreover, this association was robust to the adjustment by medication 
step, OR for C allele: 0.41, 95% CI: 0.26, 0.65, p=1.12x10-4. However, the association signals detected 
in European and admixed populations are not in LD (r2<0.01). A description of the potential functional 
implications of these variants is available at the Supporting Information.
This study describes the results of transcriptomic analyses of several datasets revealing LTBP1 as 
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levels in four datasets of ASM cells experimentally exposed to different types of GCs. Similar effects 
were detected in PBMCs obtained from asthma patients that were ICS-responders, but not in non-
responders. This suggests that ICS treatment may not induce LTBP1 expression in PBMCs from non-
responders. Additionally, the association of two variants within this gene with asthma exacerbations 
despite ICS use was found in diverse populations. 
LTBP1 encodes a member of the family of latent-transforming growth factor-beta (TGF-β) binding 
proteins. LTBP1 is involved in the regulation of the TGF-β1 activity, including its activation from a 
precursor form, folding, secretion out from the cell, and deposition at the extracellular matrix through 
interactions with fibrillin molecules5. Interestingly, TGF-β1 has been proposed to play a key role in cell 
growth and differentiation, immune response, and airway remodeling6. Specifically, increased levels of 
the active form of TGF-β1 have been detected in asthma patients, which has been suggested to recruit 
myofibroblasts triggering an increased collagen deposition and the development of subepithelial fibrosis 
in asthma7. LTBP1 has also been proposed to be involved in allergic diseases and idiopathic pulmonary 
fibrosis (IPF), where LTBP1 interacts with fibulin 1c (FBLN1), modulating lung remodeling and 
fibrosis through the regulation of TGF-β1 activation8. In fact, the inhibition of FBLN1 binding to 
LTBP1 has been proposed as a therapeutic strategy to reduce fibrotic processes8. Interestingly, genetic 
variants near or within LTBP1 are also associated with lung function measurements among participants 
from the UKBiobank9. 
We acknowledge the limited sample size of the transcriptomic datasets and the lack of functional 
experiments as major limitations of our study. Therefore, validation of the association in independent 
populations analyzing larger sample sizes and functional studies are needed. These will provide insights 
about the biological mechanisms implicating LTBP1 in ICS response and to test its clinical relevance 
predicting the treatment response. Additionally, a different gene expression profile would be obtained if 
the analyses would have been restricted only to ASM cells, as indicated by Kan et al10. 
In summary, our study revealed LTBP1 as a potential novel locus for ICS response in asthma 
patients. These results indicate that combining publicly available data from different omic sources could 
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FIGURE LEGENDS
Figure 1. Results of differential expression in response to GCs in ASM cells and PBMCs. Volcano 
plot of differential expression results in ASM cells after exposure to GCs compared to a control solution 
(panel A). Results of differential expression in PBMCs from ICS responders are shown for genes with 
significant changes in expression levels in ASM cells in response to GCs after adjusting with a false 
discovery rate (FDR) of 5% (q-value≤0.05) (panel B). Results are represented in terms of log2 fold 
change (log2 FC) (x-axis) and the logarithmic transformation of FDR (-log10 FDR) (x-axis). Genes 
significantly (q-value≤0.05) found to be up-regulated (log2 FC>0) or downregulated (log2 FC<0) are 
represented by means of green or red dots, respectively. Genes with consistent alteration of expression 
levels in ASM cells and PBMCs are labeled into white boxes. 
Dots plots of differential expression for LTBP1 in ASM cells and PBMCs (panel C). Gene expression 
levels are represented in terms of log2 counts per million (CPM) in the y-axis as dots for cases (red) and 
control (blue) samples. The median expression level is represented for each sample group by a black 
horizontal line. P-values adjusted by false discovery rate are shown (q-value).
Figure 2. Association results with asthma exacerbations despite ICS treatment for LTBP1. Forest 
plot of association effects of the SNPs rs11681246 (panel A) across the European studies and 
rs76390075 (panel C) in non-European studies. The effects are shown in terms of OR for the effect 
alleles (G and C, respectively) for each study and after performing a meta-analysis of the results by 
black boxes and a blue diamond, respectively. The 95% CI are represented by black dash lines. Results 
are not provided for BREATHE since this SNP did not pass quality control checks in this study. 
Regional plot of association results with asthma exacerbations despite ICS use among Europeans (panel 
B) and non-Europeans (panel D). The y-axis represents the logarithmic transformation of the association 
results (-log10 p-value) by chromosome position (x-axis) for each SNP as a dot. The diamond 
corresponds to the most significant variant after Bonferroni-like correction; the remaining SNPs are 
color-coded based on pairwise linkage disequilibrium (r2 values) with that SNP for Europeans (panel B) 
or Admixed American populations (panel D) from 1KGP (GRCh37/hg19 build).
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